Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface

Nature Biotechnology

Volumn 32, Issue 2, 2014, Pages 191-198

  Lewis, Steven M ^a   Wu, Xiufeng ^b   Pustilnik, Anna ^b   Sereno, Arlene ^b   Huang, Flora ^b   Rick, Heather L ^d   Guntas, Gurkan ^a   Leaver Fay, Andrew ^a   Smith, Eric M ^b   Ho, Carolyn ^b   Hansen Estruch, Christophe ^b   Chamberlain, Aaron K ^b   Truhlar, Stephanie M ^b   Conner, Elaine M ^d   Atwell, Shane ^b   Kuhlman, Brian ^a,c   Demarest, Stephen J ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIBODIES, BISPECIFIC; BIOTECHNOLOGY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; MALE; MICE; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ENGINEERING;

EID: 84893859920     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2797     Document Type: Article

References (44)

1. Chames, P & Baty, D. Bispecific antibodies for cancer therapy: The light at the end of the tunnel? mAbs 1, 539-547 (2009
2. Demarest, S.J. & Glaser, S.M. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr. Opin. Drug Discov. Devel. 11, 675-687 (2008
3. Lum, L.G. & Thakur, A. Targeting T cells with bispecific antibodies for cancer therapy. BioDrugs 25, 365-379 (2011
4. Jin, H. et al. MetMAb, the one-Armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 68, 4360-4368 (2008
5. Strop, P. et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J. Mol. Biol. 420, 204-219 (2012
6. Labrijn, A.F. et al. Efficient generation of stable bispecific IgG1 by controlled Fab-Arm exchange. Proc. Natl. Acad. Sci. USA 110, 5145-5150 (2013
7. Spiess, C. et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-Antibodies. Nat. Biotechnol. 31, 753-758 (2013
8. Bostrom, J. et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614 (2009
9. Ridgway, J.B., Presta, L.G. & Carter, P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9, 617-621 (1996
10. Klein, C. et al. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. mAbs 4, 653-663 (2012
11. Merchant, A.M. et al. An efficient route to human bispecific IgG. Nat. Biotechnol. 16, 677-681 (1998
12. Schaefer, W. et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl. Acad. Sci. USA 108, 11187-11192 (2011
13. Leaver-Fay, A., Jacak, R., Stranges, P.B. & Kuhlman, B. A generic program for multistate protein design. PLoS ONE 6, e20937 (2011
14. Havranek, J.J. & Harbury, P.B. Automated design of specificity in molecular recognition. Nat. Struct. Biol. 10, 45-52 (2003
15. Ashworth, J. et al. Computational redesign of endonuclease DNA binding and cleavage specificity. Nature 441, 656-659 (2006
16. Grigoryan, G., Reinke, A.W. & Keating, A.E. Design of protein-interaction specificity gives selective bZIP-binding peptides. Nature 458, 859-864 (2009
17. Tan, P.H., Sandmaier, B.M. & Stayton, P.S. Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency. Biophys. J. 75, 1473-1482 (1998
18. Igawa, T. et al. VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody. Protein Eng. Des. Sel. 23, 667-677 (2010
19. De Groot, A.S. & Martin, W. Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics. Clin. Immunol. 131, 189-201 (2009
20. Nahta, R., Hung, M.C. & Esteva, F.J. The HER-2-Targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 64, 2343-2346 (2004
21. Schmiedel, J., Blaukat, A., Li, S., Knochel, T. & Ferguson, K.M. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 13, 365-373 (2008
22. Ye, X. et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29, 5254-5264 (2010
23. Michaelson, J.S. et al. Anti-Tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. mAbs 1, 128-141 (2009
24. Gunasekaran, K. et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: Applications to bispecific molecules and monovalent IgG. J. Biol. Chem. 285, 19637-19646 (2010
25. Garber, E. & Demarest, S.J. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem. Biophys. Res. Commun. 355, 751-757 (2007
26. Scheer, J.M. et al. Reorienting the Fab domains of trastuzumab results in potent HER2 activators. PLoS ONE 7, e51817 (2012
27. Li, B. et al. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization. Cancer Res. 73, 6471-6483 (2013
28. Feige, M.J. et al. An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol. Cell 34, 569-579 (2009
29. Pejchal, R. et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334, 1097-1103 (2011
30. Lewis, S.M. & Kuhlman, B.A. Anchored design of protein-protein interfaces. PLoS ONE 6, e20872 (2011
31. McLellan, J.S. et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336-343 (2011
32. Gray, J.J. et al. Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. J. Mol. Biol. 331, 281-299 (2003
33. Fleishman, S.J. et al. RosettaScripts: A scripting language interface to the Rosetta macromolecular modeling suite. PLoS ONE 6, e20161 (2011
34. Cooper, S. et al. Predicting protein structures with a multiplayer online game. Nature 466, 756-760 (2010
35. Leaver-Fay, A. et al. Scientific benchmarks for guiding macromolecular energy function improvement. Methods Enzymol. 523, 109-143 (2013
36. Franklin, M.C. et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5, 317-328 (2004
37. Casimiro, D.R., Wright, P.E. & Dyson, H.J. PCR-based gene synthesis and protein NMR spectroscopy. Structure 5, 1407-1412 (1997
38. Dong, J. et al. Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-Tumor activity. J. Biol. Chem. 286, 4703-4717 (2011
39. Doern, A. et al. Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: Implications for mechanism of action in vivo. J. Biol. Chem. 284, 10254-10267 (2009
40. Powell, H.R. The Rossmann Fourier autoindexing algorithm in MOSFLM. Acta Crystallogr. D Biol. Crystallogr. 55, 1690-1695 (1999
41. Evans, P.R. An introduction to data reduction: Space-group determination, scaling and intensity statistics. Acta Crystallogr. D Biol. Crystallogr. 67, 282-292 (2011
42. McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007
43. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997
44. McRee, D.E. XtalView/Xfit-A versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125, 156-165 (1999